BioDelivery +8.6% AH; FDA approves Bunavail

|About: BioDelivery Sciences Intern... (BDSI)|By:, SA News Editor

The FDA has approved BioDelivery's (BDSI) Bunavail for the "maintenance treatment of opioid dependence." The drug is expected to launch late in Q3.

BioDelivery estimates peak U.S. sales potential of up to $250M. A deal has been reached with Ashfield Market Access to "provide managed markets and trade support" for Bunavail.